All Drug Development articles – Page 25
-
NewsNew treatment for metabolic dysfunction-associated steatohepatitis
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
-
NewsNew AI model could help to overcome antibiotic resistance
Six molecules that had potent antibacterial effect against one of the world’s most dangerous antibiotic-resistant bacteria were generated.
-
NewsFGF2 and SOX17 enable more efficient stem cell differentiation
The discovery of two proteins that effectively mature hiPSCs into endothelial cells may have a range of research and clinical benefits.
-
NewsNew strategies to overcome CAR T-cell resistance in AML cells
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
-
NewsThe mechanism of PARP inhibitor action is identified
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
-
ArticleDeveloping an mRNA therapy for Duchenne muscular dystrophy
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
-
NewsEvaluating novel gene therapies in a whole human liver
Use of the whole liver could revolutionise the development of viral vectors, providing more effective treatments for inherited diseases.
-
ArticleStreamlining the path from lab to market with 3D bioprinting
In this Q&A, Dr Vidmantas Šakalys, CEO of Vital3D, provides insights into the potential of 3D bioprinting to revolutionise the traditional drug development process, facilitating more accurate models and limiting the use of animal testing.
-
ArticleWomen in Stem with Katherine Tran
Introducing Kratherine Tran! Katherine joined the SCIEX team with a strong desire to further the company’s mission of delivering solutions to advance human wellness. Her main area of interest is within mass spectrometry-based proteomics from which she has accumulated a wealth of knowledge and experience in this space over the ...
-
NewsNew insights into PD-1 formation could greatly improve treatments
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
-
ArticleBreakthrough for pancreatic cancer treatment
Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.
-
ArticleWomen in Stem with Leila Jaafar
After gaining her PhD in Biophysics as an International Max-Planck Research School scholar, Leila joined the nuclear field in 2006, starting as an engineer in radiation protection and neutron fluence. Throughout Leila’s career, she has worked across multiple disciplines as a technical project lead in nuclear engineering, lastly in the ...
-
ArticleThe future of cancer immunotherapy with Elicio Therapeutics
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted ...
-
ArticleWomen in Stem with Dr Amber D. Van Laar
Dr Amber Van Laar shares her remarkable journey in STEM. From a childhood fascination with science and medicine to a pivotal role as VP Clinical Development, AskBio. In this interview, she explores the profound impact of her early exposure to neuro-oncology, the challenges faced as a physician-scientist, and the pursuit ...
-
WebinarIon Channel Drug Discovery - Recent Advances in Novel Non-Opioid Pain Research
Watch this webinar to learn about recently published research toward the advancement of non-opioid analgesics targeting the Nav1.8 ion channel, a validated pain target primarily found in peripheral nociceptors.
-
ArticleGamma delta T cells: a rising star in cancer therapy
Gamma delta (γδ) T cells comprise a distinct and powerful subpopulation of T cells, bridging innate and adaptive immunity, that holds great promise for treating cancer. IN8Bio co-founder and CEO William Ho and COO Kate Rochlin discuss what makes γδ T cells unique, how preclinical research suggests their antitumour activity ...
-
ReportBeyond the lab: artificial intelligence
Amidst the transformative era of AI in drug discovery, this report focuses on recent advancements, notably the development of highly accurate drug target models, and how AI is revolutionising precision in identifying drug targets.
-
NewsKey insights into vaccine development for herpesviruses
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.
-
NewsCombatting HIV using gene therapy
Researchers have created a nanomedicine loaded with siRNAs, which demonstrated a 73 percent reduction in HIV replication.
-
NewsMitigating oxidative stress in neurodegenerative diseases
Researchers have found that using protein-like polymers to inhibit the Keap1/Nrf2 PPI is a powerful therapeutic strategy.